Physician profile
Barry E Slitzky
NPI 1639263726
$2,785.94
in general payments reported to CMS, 2019-2025
23 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $115 · 2021: $58.60 · 2022: $143 · 2023: $325 · 2024: $540 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.01 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.73 | 2019-2025 | Linzess, Creon, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $425.14 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $250.15 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.17 | 2019-2025 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $198.85 | 2025 | Voquezna |
| Genzyme Corporation | $126.47 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $69.98 | 2025 | Iqirvo |
| Celltrion USA INC. | $66.15 | 2024-2025 | Zymfentra, Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.30 | 2023-2024 | Cyltezo |
| Celgene Corporation | $63.21 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $60.83 | 2025 | Ibsrela |
| Pfizer INC. | $60.31 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $46.97 | 2019-2025 | |
| Exact Sciences Corporation | $40.15 | 2024 | Cologuard Collection Kit |
| Ucb, INC. | $35.41 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $29.43 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $27.24 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $23.23 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $22.24 | 2023 | Linzess |
| Medtronic, INC. | $20.34 | 2021 | |
| Allergan, INC. | $19.29 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.26 | 2019 | |
| Merck Sharp & Dohme LLC | $16.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Slitzky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.